Celebrex Set For Rebound; Silver Lining For Pfizer After Bextra Pulled

Celebrex is in a good position to reclaim its position as the leading anti-arthritic therapy following the conclusion of FDA's safety review of the non-steroidal anti-inflammatory drug class